Cihan B. Altın

Medical Point Hospital, Türkiye
Izmir, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Baseline Clinical Characteristics of Patients from the Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Türkiye (ETAF-TR) Study.

Baseline Clinical Characteristics of Patients from the Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Türkiye (ETAF-TR) Study.

Journal: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

Published: December 12, 2025

Rationale and Design of the Türkiye Heart Failure (TURK-HF) Registry.

Rationale and Design of the Türkiye Heart Failure (TURK-HF) Registry.

Journal: Clinical cardiology

Published: July 28, 2025

Exploring hypertension awareness in physicians: a cross-sectional study from Turkey.

Exploring hypertension awareness in physicians: a cross-sectional study from Turkey.

Journal: Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Published: June 04, 2025

Pentraxin 3: A Marker for the Presence and Severity of Coronary Artery Disease.

Pentraxin 3: A Marker for the Presence and Severity of Coronary Artery Disease.

Journal: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

Published: March 04, 2025

Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye.

Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye.

Journal: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

Published: December 02, 2024

Diagnostic Potential of CTRP5 and Chemerin for Coronary Artery Disease: A Study by Coronary Computed Tomography Angiography.

Diagnostic Potential of CTRP5 and Chemerin for Coronary Artery Disease: A Study by Coronary Computed Tomography Angiography.

Journal: Diagnostics (Basel, Switzerland)

Published: November 21, 2024

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study.

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study.

Journal: Clinical cardiology

Published: September 02, 2024

Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study.

Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study.

Journal: ESC heart failure

Published: February 04, 2024

Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.

Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.

Journal: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

Published: March 14, 2023

Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study.

Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study.

Journal: Cardiovascular drugs and therapy

Published: January 19, 2023

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study.

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study.

Journal: Cardiovascular drugs and therapy

Published: November 15, 2022

The Safety and Tolerability of Nebivolol in Hypertensive Patients with Coronary Artery Disease and Left Ventricular Ejection Fraction ≥ 40%: A Population-Based Cohort Study (Nebivolol-TR Study).

The Safety and Tolerability of Nebivolol in Hypertensive Patients with Coronary Artery Disease and Left Ventricular Ejection Fraction ≥ 40%: A Population-Based Cohort Study (Nebivolol-TR Study).

Journal: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

Published: November 01, 2022

Showing 1-12 of 58

Last Updated: 09/26/2026